Nelson M - Search Results

1

Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.

Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V. Tashima K, et al. Among authors: nelson m. AIDS. 2008 Jan 11;22(2):275-9. doi: 10.1097/QAD.0b013e3282f21b9d. AIDS. 2008. PMID: 18097230 Clinical Trial.

2

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C. Arribas JR, et al. Among authors: nelson m. AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944. AIDS. 2010. PMID: 20010070 Clinical Trial.

3

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Fätkenheuer G, et al. Among authors: nelson m. N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154. N Engl J Med. 2008. PMID: 18832245 Free article.

4

Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals.

Smith CJ, Staszewski S, Sabin CA, Nelson M, Dauer B, Gute P, Johnson MA, Phillips AN, Gazzard B. Smith CJ, et al. Among authors: nelson m. J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1155-9. doi: 10.1097/01.qai.0000135958.80919.e4. J Acquir Immune Defic Syndr. 2004. PMID: 15319675

5

The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.

Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM; UK HIV Drug Resistance Database; UK CHIC study. Mackie NE, et al. AIDS. 2013 Sep 10;27(14):2245-53. doi: 10.1097/QAD.0b013e3283636179. AIDS. 2013. PMID: 24157905

6

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.

Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Bower M, Gazzard B. Portsmouth S, et al. Among authors: nelson m. AIDS. 2003 Jul 25;17(11):F17-22. doi: 10.1097/00002030-200307250-00001. AIDS. 2003. PMID: 12853764

7

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

Waters L, Fisher M, Winston A, Higgs C, Hadley W, Garvey L, Mandalia S, Perry N, Nicola M, Nelson M. Waters L, et al. Among authors: nelson m. AIDS. 2011 Jan 2;25(1):65-71. doi: 10.1097/QAD.0b013e328341685b. AIDS. 2011. PMID: 21099666 Clinical Trial.

8

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.

Nelson M, Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard B, Hill A, van Delft Y, Vingerhoets J, Stark T, Marks S. Nelson M, et al. AIDS. 2011 Jan 28;25(3):335-40. doi: 10.1097/QAD.0b013e3283416873. AIDS. 2011. PMID: 21150563

9

Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.

Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, Gazzard B. Maitland D, et al. Among authors: nelson m. AIDS. 2005 Jul 22;19(11):1183-8. doi: 10.1097/01.aids.0000176218.40861.14. AIDS. 2005. PMID: 15990571 Clinical Trial.

10

Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.

Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Powles T, et al. Among authors: nelson m. AIDS. 2002 Mar 8;16(4):531-6. doi: 10.1097/00002030-200203080-00003. AIDS. 2002. PMID: 11872995

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,492 results

Search Page

Filters